BridgeBio Pharma, Inc. (NASDAQ:BBIO) reported insider sales by Chief Executive Officer Neil Kumar on April 9 and April 10, according to a Form 4 filed with the Securities and Exchange Commission. The combined value of those dispositions was $5,968,780.
On April 9, Kumar sold shares across multiple tranches with a reported price range of $73.15 to $76.18. The filing lists the following breakdowns for that date: 7,200 shares at a weighted average price of $73.6444, 5,300 shares at a weighted average price of $74.6044, and 7,500 shares at a weighted average price of $75.5548. In addition, the filing records 7,072 shares sold at a weighted average price of $73.6427, 5,128 shares at a weighted average price of $74.5669, and 7,800 shares at a weighted average price of $75.5287.
On April 10, the Form 4 shows two blocks of 20,000 shares each sold at weighted average prices of $74.6048 and $74.6038, respectively. The filing states that all of these sales were executed indirectly through trusts in which Kumar is a co-trustee, and that they were made pursuant to a Rule 10b5-1 trading arrangement adopted on March 31, 2025.
Following the transactions, Kumar retains indirect holdings through the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, and he also continues to hold 234,451 shares directly.
Market context and company performance noted in filing summary
According to InvestingPro data cited alongside the filing, BridgeBio shares have risen to $77.87, representing a 130% gain over the past year. InvestingPro Tips referenced in the filing state the company is not currently profitable but carries a "GOOD" financial health score. The company’s next earnings report is noted as scheduled for April 30.
Recent operational, clinical and regulatory developments
The filing accompaniment highlights several contemporaneous developments for BridgeBio. Barclays has reiterated an Overweight rating and projects first-quarter U.S. revenue for Attruby at $175 million, above consensus, and full-year 2026 U.S. revenue at $912 million, also above consensus. RBC Capital has initiated coverage with an Outperform rating and a $100 price target, citing the uptake of Attruby.
The company reported continued clinical benefit for acoramidis over 54 months in patients with transthyretin amyloid cardiomyopathy, as presented at a major scientific conference. In regulatory activity, BridgeBio submitted a New Drug Application to the U.S. Food and Drug Administration for its oral BBP-418 ahead of its initial timetable.
Analyst coverage also includes Buy ratings from H.C. Wainwright and Jefferies, both with $100 price targets. Jefferies is noted in the filing as projecting potential peak sales for the BBP-418 program of over $1 billion.
What the filing documents and coverage state
- The sales on April 9 and April 10 were executed indirectly through trusts for which Kumar is co-trustee and were carried out under a March 31, 2025, Rule 10b5-1 trading plan.
- The combined value of the disclosed transactions is $5,968,780.
- Kumar continues to hold shares both indirectly and directly, including 234,451 shares held personally.
These disclosures provide a contemporaneous snapshot of insider activity alongside ongoing analyst coverage and regulatory filings for BridgeBio Pharma.